ACORDA THERAPEUTICS, INC. and COMPUTERSHARE TRUST COMPANY, N.A., as Rights Agent Rights Agreement Dated as of August 31, 2017Rights Agreement • September 1st, 2017 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Rights Agreement, dated as of August 31, 2017 (as amended, supplemented or otherwise modified from time to time, the “Agreement”), between Acorda Therapeutics, Inc., a Delaware corporation (the “Company”), and COMPUTERSHARE TRUST COMPANY, N.A., a federally chartered trust company, as rights agent (the “Rights Agent”).
AT THE MARKET OFFERING AGREEMENT January 13, 2021At the Market Offering Agreement • January 13th, 2021 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Acorda Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:
ASSET BASED LENDINGCredit Agreement • August 4th, 2016 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
CREDIT AGREEMENT dated as of June 1, 2016 (as it may be amended or modified from time to time, this "Agreement") among ACORDA THERAPEUTICS, INC., a Delaware corporation (the "Company"), CIVITAS THERAPEUTICS, INC., a Delaware corporation ("Civitas"), and NEURONEX, INC., a Delaware corporation ("Neuronex", and together with the Company, Civitas, and Neuronex, each, individually, a "Borrower" and collectively, the "Borrowers"), the other Loan Parties party hereto, the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent.
ACORDA THERAPEUTICS, INC. AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of June 23, 2014 to Indenture Dated as of June 23, 2014 1.75% Convertible Senior Notes due 2021First Supplemental Indenture • June 23rd, 2014 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
FIRST SUPPLEMENTAL INDENTURE dated as of June 23, 2014 (this “Supplemental Indenture”) between ACORDA THERAPEUTICS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01), supplementing the Indenture dated as of June 23, 2014 between the Company and the Trustee (the “Base Indenture” and the Base Indenture, as amended and supplemented by this Supplemental Indenture, and as it may be further amended or supplemented from time to time with respect to the Notes, the “Indenture”).
Acorda Therapeutics, Inc. [•] Shares Common Stock UNDERWRITING AGREEMENT dated [•], 2006 Banc of America Securities LLC Lazard Capital Markets LLC Piper Jaffray & Co. SG Cowen & Co., LLCUnderwriting Agreement • February 3rd, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
ACORDA THERAPEUTICS, INC., AS ISSUER, AND AS TRUSTEE, SUBORDINATED INDENTURE DATED AS OF [ , ] SUBORDINATED DEBT SECURITIESSubordinated Indenture • September 11th, 2020 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
THIS INDENTURE, dated as of [ , ], between Acorda Therapeutics, Inc., a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), and [ ], as trustee (the “Trustee,” which term shall include any successor trustee appointed pursuant to Article 7 of this Indenture).
Acorda Therapeutics, Inc. 3,300,000 Shares Common Stock UNDERWRITING AGREEMENT dated February 12, 2008 Deutsche Bank Securities Inc.Underwriting Agreement • February 14th, 2008 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
September 1, 2020 Kerry ClemEmployment Agreement • September 9th, 2021 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
We are delighted to present this letter agreement (“Agreement”), setting out the terms of your continued employment with Acorda Therapeutics, Inc. (the "Company") as Executive Vice President, Sales, Market Access and Operations. If these terms are acceptable, please sign and date the copy of this letter provided herewith and return it to me at your first convenience. If you accept the terms offered herein, this Agreement shall be deemed to be effective as of September 1, 2020 (the "Effective Date").
Date: 26, September 2003 ELAN CORPORATION, PLC. AND ACORDA THERAPEUTICS, INC. AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • July 20th, 2011 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree that each of the MS Agreement and the SCI Agreement, and all of the terms, conditions and provisions of the MS Agreement and the SCI Agreement, are hereby superceded and replaced and restated in their entirety by this Agreement and the Supply Agreement and the terms, conditions and provisions hereof and thereof, as of the Amendment Date, as follows and as set forth in the Supply Agreement:
ACORDA THERAPEUTICS, INC.Underwriting Agreement • June 23rd, 2014 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Acorda Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you (the “Underwriter”) $300,000,000 principal amount of its 1.75% Convertible Notes due 2021 (the “Underwritten Securities”) and, at the option of the Underwriter, up to an additional $45,000,000 principal amount of its 1.75% Convertible Notes due 2021 (the “Option Securities”) if and to the extent that the Underwriter shall have determined to exercise the option to purchase such 1.75% Convertible Notes due 2021 granted to the Underwriter in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities.” The Securities will be convertible into cash, shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), or a combination of cash and shares of Common Stock (any shares of Common Stock issuable upon conversion of the Securities, including, for the avoidance of doubt, any additional shares deliverable upon conv
ACORDA TherapeuticsEmployment Agreement • October 5th, 2005 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
We are delighted to present this letter agreement, setting out the terms of your continued employment with Acorda Therapeutics, Inc. (the “Company”) as President, Director and Chief Executive Officer. If these terms are acceptable, please sign and date the copy of this letter provided herewith and return it to me at your first convenience. If you accept the terms offered herein, this Agreement shall be deemed to be effective as of January 1, 2002 (the “Effective Date”).
Date: 26, September 2003 ELAN CORPORATION, PLC. AND ACORDA THERAPEUTICS, INC. SUPPLY AGREEMENTSupply Agreement • January 25th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
LICENSE AGREEMENT by and between RUSH-PRESBYTERIAN-ST. LUKE’S MEDICAL CENTER and ACORDA THERAPEUTICS, INC.License Agreement • August 8th, 2011 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT effective as of September 26, 2003 (“Effective Date”), by and between RUSH-PRESBYTERIAN-ST. LUKE’S MEDICAL CENTER, an Illinois not-for-profit corporation and having its principal office at 1725 W. Harrison St. Chicago, Ill. 60612 (“RUSH”) and ACORDA THERAPEUTICS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 15 Skyline Drive, Hawthorne, New York 10532 (“ACORDA”).
Re: Amendment to December 19, 2005 Employment AgreementEmployment Agreement • May 14th, 2007 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
This letter serves as an amendment to your letter agreement, dated December 19, 2005, with Acorda Therapeutics, Inc. (the “Agreement”), in accordance with paragraph 8(b) of the Agreement. Specifically, the Agreement is amended as follows, effective May 10, 2007:
LICENSE AGREEMENTLicense Agreement • January 25th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Report royalty payment information to the Cornell Research Foundation, Inc (CRF) using the report format or facsimile attached to these instructions. This minimal information must be provided in order to correctly record royalty related events required by your license agreement with CRF.
LICENSE AGREEMENTLicense Agreement • August 8th, 2011 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into as of November 12, 2002 (the “Effective Date”), by and between Acorda Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 15 Skyline Drive, Hawthorne, New York, USA 10532 (“Acorda”), and CeNeS Pharmaceuticals, PLC, a corporation organized and existing under the laws of the United Kingdom and having a principal place of business at Compass House, Vision Park, Chivers Way, Histon, Cambridge CB4 9ZR, England (“CeNeS”).
Acorda Therapeutics, Inc. [___] Shares Common Stock UNDERWRITING AGREEMENT dated [___], 2003 Banc of America Securities LLC Lazard Frères & Co. LLC RBC Dain Rauscher Inc.Underwriting Agreement • November 6th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Employment AgreementEmployment Agreement • January 5th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
We are delighted to present this letter agreement, setting out the terms of your continued employment with Acorda Therapeutics, Inc. (the “Company”) as Executive Vice President, General Counsel and Corporate Secretary. If these terms are acceptable, please sign and date the copy of this letter provided herewith and return it to me at your first convenience. If you accept the terms offered herein, this Agreement shall he deemed to be effective as of December 19, 2005 (the “Effective Date”).
November 7, 2011 David Lawrence Warwick, NY 10990 Re: Amendment to Employment Agreement Dear David:Employment Agreement • February 28th, 2012 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
This letter serves as an amendment to your employment letter agreement, dated December 19, 2005, with Acorda Therapeutics, Inc., as previously amended (the “Agreement”), in accordance with paragraph 8(b) of the Agreement. Specifically, the Agreement is amended as follows, effective as of the date written above:
ContractAsset Purchase Agreement • May 9th, 2014 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Commission.
AMENDMENT No. 1 TO RUSH PAYMENTS AGREEMENTRush Payments Agreement • January 25th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT, dated as of October 27, 2003, by and between Acorda Therapeutics, Inc. (“Acorda”) and Elan Corporation, plc. (“Elan”) amends the Rush Payments Agreement effective as of September 26, 2003 (the “Payments Agreement”) by and between Acorda and Elan.
SECURITIES AMENDMENT AGREEMENT AMONG ELAN CORPORATION, PLC, ELAN INTERNATIONAL SERVICES, LTD. AND ACORDA THERAPEUTICS, INC.Securities Amendment Agreement • October 5th, 2005 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
IN CONSIDERATION OF THE MUTUAL COVENANTS CONTAINED HEREIN, AND OTHER GOOD AND VALUABLE CONSIDERATION, THE RECEIPT AND ADEQUACY OF WHICH ARE HEREBY ACKNOWLEDGED, IT IS HEREBY AGREED AS FOLLOWS:
RUSH PAYMENTS AGREEMENTRush Payments Agreement • January 25th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
REFERENCE IS MADE to (i) the License Agreement effective as of September 26, 2003, by and between RUSH-PRESBYTERIAN-ST. LUKE’S MEDICAL CENTER, an Illinois not-for-profit corporation and having its principal office at 1725 W. Harrison St. Chicago, Ill. 60612 (“Rush”), and ACORDA THERAPEUTICS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 15 Skyline Drive, Hawthorne, New York 10532 (“Acorda”), including the Side Agreement attached thereto as Exhibit 1.31 by and among Rush, Acorda and Elan (as defined below) (the “Side Agreement”), a copy of which is attached as Exhibit A hereto (the “Rush/Acorda License”); and (ii) the Amended and Restated License Agreement effective as of September 26, 2003 by and between Acorda and ELAN CORPORATION, PLC., a public limited company incorporated under the laws of Ireland and having its registered office at Lincoln House, Lincoln Place, Dublin 2, Ireland (“Elan”) (the “Elan/Acorda Lice
TERMINATION AND ASSIGNMENT AGREEMENT ELAN CORPORATION, PLC ELAN INTERNATIONAL SERVICES, LTD. ACORDA THERAPEUTICS, Inc. MS RESEARCH AND DEVELOPMENT CORPORATIONTermination and Assignment Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
IN CONSIDERATION OF THE MUTUAL COVENANTS CONTAINED HEREIN, AND OTHER GOOD AND VALUABLE CONSIDERATION, THE RECEIPT AND ADEQUACY OF WHICH ARE HEREBY ACKNOWLEDGED, IT IS HEREBY AGREED AS FOLLOWS:
LICENSE AGREEMENTLicense Agreement • May 9th, 2011 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • England
THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into as of this 19th day of December, 2003 (the “Effective Date”) among ACORDA THERAPEUTICS, INC., a corporation organized and existing under the laws of the state of Delaware having a principal place of business at 15 Skyline Drive, Hawthorne, New York 10532, USA (“Acorda”), CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED, an entity organized and existing under the laws of England having a registered address at The Old Schools, Trinity Lane, Cambridge CB2 1TS, UK. (“CUTS”), and KING’S COLLEGE LONDON, an Institution incorporated by Royal Charter, of Strand, London, WC2R 2LS, UK (“KCL”; CUTS and KCL may be collectively referred to as the “Institutions”). Each of Acorda, CUTS and KCL may be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED LICENSE AGREEMENT by and between CANADIAN SPINAL RESEARCH ORGANIZATION and ACORDA THERAPEUTICS, INC.License Agreement • October 5th, 2005 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
LICENSE AGREEMENT BETWEEN ACORDA THERAPEUTICS, INC. AND THE MAYO FOUNDATION FOR EDUCATION AND RESEARCH Dated: September 8, 2000License Agreement • October 5th, 2005 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Minnesota
THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of September 8, 2000 (the “Effective Date”), by and between Acorda Therapeutics, Inc., a Delaware corporation, having offices at 15 Skyline Drive, Hawthorne, New York 10532, (“ACORDA”) and The Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation located at 200 First Street SW, Rochester, Minnesota 55905 (“MAYO”).
LABORATORY SERVICES AGREEMENTLaboratory Services Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Laboratory Services Agreement (“Agreement”) effective as of April 1, 2003 (the “Effective Date”) is between Acorda Therapeutics, Inc. with an address at 15 Skyline Drive, Hawthorne, New York 10532, USA (“Acorda”) and Cardinal Health PTS, Inc. with an address of 160 Magellan Labs Ct., Morrisville, North Carolina, USA (“Cardinal Health”).
AGREEMENT RELATING TO ADDITIONAL TRADEMARKTrademark License Agreement • January 25th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Agreement Relating to Additional Trademark (this “Agreement”) is made as of July ___, 2005 (the “Effective Date”) by and between Elan Pharmaceuticals, Inc. (“EPI”) and Acorda Therapeutics, Inc. (“Acorda”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Asset Purchase Agreement by and between EPI and Acorda dated as of July 21, 2004 (the “Asset Purchase Agreement”).
ContractLicense Agreement • January 25th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Minnesota
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Commission.
COLLABORATION AGREEMENT by and between TEVA PHARMACEUTICAL INDUSTRIES LTD. and ACORDA THERAPEUTICS, INC.Collaboration Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This letter shall confirm our agreement regarding a possible collaboration agreement to develop, co-promote and commercialize in the United States (including its possessions and territories), Canada and Mexico (collectively, the “Territory”) all finished pharmaceutical products that contain Acorda’s chemical compound referred to as fampridine (the “Fampridine Agreement”).
AMENDMENT NO. 1 AGREEMENT to the Amended and Restated License Agreement dated 26 September 2003 between Elan Corporation, plc and Acorda Therapeutics, Inc. and to the Supply Agreement dated 26 September 2003 between Elan Corporation, plc and Acorda...Amendment No. 1 Agreement • August 10th, 2009 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This AMENDMENT NO. 1 AGREEMENT and CONSENT TO SUBLICENSE (the “Amendment and Consent Agreement”) dated as of the 30th day of June, 2009 (the “Effective Date”) is by and among Elan Pharma International Limited, a company incorporated under the laws of Ireland and having its registered office at Monksland, Athlone, County Westmeath, Ireland (“Elan”), Acorda Therapeutics, Inc., a Delaware corporation with an office at 15 Skyline Drive, Hawthorne, New York 10532, USA (“Acorda”), and Biogen Idec International GmbH , a Swiss company with an office at Landis & Gyr Strasse 3, CH-6300 Zug, Switzerland (“Biogen”). Elan, Acorda and Biogen are each a “Party” and collectively, the “Parties”.
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • January 25th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
This Assignment and Assumption Agreement (this “Agreement”) is entered into this 21st day of July 2004, by and among Acorda Therapeutics, Inc. (“Buyer’’), Elan Pharmaceuticals, Inc. (together with its affiliates, “Elan”), on behalf of itself and its affiliates, and Novartis Pharma AG (together with its affiliates, “Novartis”), on behalf of itself and its affiliates.
AERES BIOMEDICAL LIMITED ACORDA THERAPEUTICSResearch Collaboration and Commercialisation Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • England
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Commission.
LICENSE AGREEMENTLicense Agreement • January 25th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New Jersey
THIS LICENSE AGREEMENT (this “Agreement”), made the 17th day of April, 1991 by and between SANDOZ PHARMA LTD., a Swiss corporation having its principal place of business at Lichtstrasse 35, CH-4002 Basle, Switzerland (“Sandoz Pharma”) and ATHENA NEUROSCIENCES, INC. a Delaware corporation having its principal place of business at 800F Gateway Boulevard, South San Francisco, California (“Licensee”),
